Now that we know hitting the GLP-1 weight loss plateau is normal and to be expected, give yourself a pat on the back for lowering your weight and letting your body build a healthier, more efficient version
The phase 3 SELECT trial enrolled adults aged 45 years or older with a BMI of 27 kg/m or higher and established cardiovascular disease
Our prior authorization support extends from submission to your coverage provider through to approval
For patients who qualify, consider transitioning to an FDA-approved GLP-1 receptor agonist when supply, insurance coverage, and affordability permit
If cognitive performance, focus, memory, or mental fatigue is the primary concern in the absence of significant anxiety, Semax is the more appropriate choice